129 related articles for article (PubMed ID: 6056377)
1. Therapeutic response in oral dosage forms.
Morrison AB
Med Serv J Can; 1967 Mar; 23(3):349-59. PubMed ID: 6056377
[No Abstract] [Full Text] [Related]
2. Therapeutic response to oral dosage forms.
Ruedy J
Med Serv J Can; 1967 Mar; 23(3):360-2. PubMed ID: 6056378
[No Abstract] [Full Text] [Related]
3. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
Jimenez FA
Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
[No Abstract] [Full Text] [Related]
4. Influence of compounding on bioavailability.
Riviere JE
J Am Vet Med Assoc; 1994 Jul; 205(2):226-31. PubMed ID: 7928583
[No Abstract] [Full Text] [Related]
5. [Medicines raw materials used in compounding medicines: an update of the legislation].
Huyghebaert C; Leuckx S
J Pharm Belg; 2010 Mar; (1):16-8. PubMed ID: 20429391
[No Abstract] [Full Text] [Related]
6. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms.
Siewert M; Dressman J; Brown CK; Shah VP; ;
AAPS PharmSciTech; 2003; 4(1):E7. PubMed ID: 12916916
[No Abstract] [Full Text] [Related]
7. Pharmaceutical controls for drug availability.
Bethel RF
Med Serv J Can; 1967 Mar; 23(3):337-45. PubMed ID: 6061040
[No Abstract] [Full Text] [Related]
8. [Maintaining standards of good compounding (N.B.F.)].
Castoldi B; Fumagalli A; Mazzoldi G
Boll Chim Farm; 1978 Dec; 117(12):689-99. PubMed ID: 752351
[No Abstract] [Full Text] [Related]
9. Proposed current good manufacturing practice and supplemental regulations.
Korun FD
Bull Parenter Drug Assoc; 1976; 30(3):139-42. PubMed ID: 1268432
[No Abstract] [Full Text] [Related]
10. Panel discussion: in process control and inspection for quality assurance. 3.
Brofazi FR
Bull Parenter Drug Assoc; 1968; 22(2):90-6. PubMed ID: 5649572
[No Abstract] [Full Text] [Related]
11. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
Glass BD; Haywood A
J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
[TBL] [Abstract][Full Text] [Related]
12. The presence of microorganisms in some common excipients used in tablet formulation.
Obuekwe IF; Eichie F
Acta Pol Pharm; 2006; 63(2):121-5. PubMed ID: 17514875
[TBL] [Abstract][Full Text] [Related]
13. [Summary of the discussion on the subject of: "technical problems in the production and use of infusion solutions"].
Klin Anasthesiol Intensivther; 1977; (14):95-105. PubMed ID: 926695
[No Abstract] [Full Text] [Related]
14. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organ Tech Rep Ser; 1999; 885():i-vi, 1-156. PubMed ID: 10352573
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations after oral administration of different pharmaceutical preparations of clomethiazole.
Fischler M; Frisch EP; Ortengren B
Acta Pharm Suec; 1973 Dec; 10(6):483-92. PubMed ID: 4773115
[No Abstract] [Full Text] [Related]
16. PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing.
Allen LV
Int J Pharm Compd; 2018; 22(2):92. PubMed ID: 29877856
[No Abstract] [Full Text] [Related]
17. [Round table on the "norms for good drug compounding"].
Boll Chim Farm; 1970 Nov; 109(11):635-52. PubMed ID: 5515584
[No Abstract] [Full Text] [Related]
18. Crushed medications: an emerging guideline.
Simpson C
Aust Nurs J; 2005 Jul; 13(1):21-3. PubMed ID: 16502943
[No Abstract] [Full Text] [Related]
19. When does compounding become manufacturing?
Gushee J
J Am Vet Med Assoc; 1994 Jul; 205(2):235-6. PubMed ID: 7928585
[No Abstract] [Full Text] [Related]
20. [Progress in galenicals (1962-1964)].
Chalabala M; Malý J; Zácek H
Pharmazie; 1966 Feb; 21(2):73-95. PubMed ID: 4861050
[No Abstract] [Full Text] [Related]
[Next] [New Search]
